Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24680757 | 0.88 | PIK3CA (0.66) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24680676 | 0.79 | PIK3CA (0.51) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL24679816 | 0.77 | PIK3CA (0.68) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24680533 | 0.77 | PIK3CA (0.68) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30322667 | 0.76 | PIK3CA (0.63) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24680669 | 0.75 | PIK3CA (0.66) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30090482 | 0.75 | PIK3CA (0.66) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24908857 | 0.75 | PIK3CA (0.66) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30090574 | 0.75 | PIK3CA (0.63) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL23895590 | 0.75 | PIK3CA (0.67) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |